We also assessed RAS profiles in the subgroup of 92 patients not receiving RAS inhibitors (Table S1) and found that the difference in classical RAS activation by severity had vanished (severe versus non-severe COVID-19, respectively: 40 versus 31 pmol/L angiotensin I, p = 0.251; and 76 versus 99 pmol/L angiotensin II, p = 0.833; Table 2A, Table S2). The gene discussed is AGT; the disease is COVID-19.